CTOs on the Move

Biomatrix

www.biomatrix.com

 
Biomatrix, Inc., together with its subsidiaries in Canada, Europe and Asia, develops, manufactures, markets and sells a series of proprietary viscoelastic products called hylans that are used in therapeutic medical applications and skin care. Hylans are
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

SpineFrontier

SpineFrontier Inc. is a growing medical device company that designs, develops and markets implants and instruments that equip surgeons to perform the least invasive spine surgery. SpineFrontier`s innovative and disruptive technologies and techniques apply the Less Exposure Surgery (LES) philosophy to solve clinical problems and make the surgeries safer for the patient and easier for the surgeon. Surgeries can be done in an outpatient center and patients can be discharged same day with rapid recovery, due to less disruption of normal tissues and less time in surgery. We believe LESS is more. LESS time in treatment and recovery is MORE time in action for our patients and surgeons. SpineFrontier is headquartered in Beverly, Massachusetts. It was founded in 2006, and released its first products in 2008. SpineFrontier is a KICventures portfolio company and the exclusive manufacturer of LESS technologies and instruments for surgeon members practicing in the LESS Institute global outpatient network.

Athera

Athera Incorporated is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Serim Research Corp

Serim Research Corp is a Elkhart, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reva Medical

Founded in 1998, REVA Medical is dedicated to developing minimally invasive medical devices that leverage its proprietary biomaterial and stent technologies to improve the treatment of coronary artery disease. Guided by an executive management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA’s initial focus is the development of a drug-eluting bioresorbable coronary scaffold to advance the treatment of cardiovascular disease, the leading cause of death worldwide.